MA27326A1 - Derives de piperidine et leur utilisation comme inhibiteurs selectifs de la liaison de mip-1 alpha a son recepteur ccr1 - Google Patents

Derives de piperidine et leur utilisation comme inhibiteurs selectifs de la liaison de mip-1 alpha a son recepteur ccr1

Info

Publication number
MA27326A1
MA27326A1 MA28049A MA28049A MA27326A1 MA 27326 A1 MA27326 A1 MA 27326A1 MA 28049 A MA28049 A MA 28049A MA 28049 A MA28049 A MA 28049A MA 27326 A1 MA27326 A1 MA 27326A1
Authority
MA
Morocco
Prior art keywords
alpha
binding
mip
ccr1 receptor
piperidine derivatives
Prior art date
Application number
MA28049A
Other languages
English (en)
Inventor
Laura Cook Blumberg
Matthew Frank Brown
Matthew Merrill Hayward
Christopher Stanley Poss
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA27326A1 publication Critical patent/MA27326A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

DEPOSANT Société dite : PFIZER PRODUCTS INC. REVENDICATIONS DE PRIORITES US 18 juillet 2002 60/397,108 Dérivés de pipéridine et leur utilisation comme inhibiteurs sélectifs de la liaison de MIP-1 alpha à son récepteur CCR1 Un composé de formule (I) dans laquelle a, b, c, R1, R3,R4, R5, R6, R7, Q, W, Y et Z répondent aux définitions précitées, utile comme inhibiteur puissant et sélectif de la liaison de MlP-l(alpha) (CCL3) à son récepteur CCR1 présent sur des cellules inflammatoires et immunomodulatrices (de préférence les leucocytes et lymphocytes).
MA28049A 2002-07-18 2005-01-18 Derives de piperidine et leur utilisation comme inhibiteurs selectifs de la liaison de mip-1 alpha a son recepteur ccr1 MA27326A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39710802P 2002-07-18 2002-07-18

Publications (1)

Publication Number Publication Date
MA27326A1 true MA27326A1 (fr) 2005-05-02

Family

ID=30770997

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28049A MA27326A1 (fr) 2002-07-18 2005-01-18 Derives de piperidine et leur utilisation comme inhibiteurs selectifs de la liaison de mip-1 alpha a son recepteur ccr1

Country Status (24)

Country Link
US (1) US20040063759A1 (fr)
EP (1) EP1534677A1 (fr)
JP (1) JP2005537279A (fr)
KR (1) KR20050021497A (fr)
CN (1) CN1668592A (fr)
AP (1) AP2005003200A0 (fr)
AR (1) AR040583A1 (fr)
AU (1) AU2003242941A1 (fr)
BR (1) BR0312946A (fr)
CA (1) CA2492651A1 (fr)
EC (1) ECSP055547A (fr)
HN (1) HN2003000222A (fr)
IL (1) IL166010A0 (fr)
IS (1) IS7614A (fr)
MA (1) MA27326A1 (fr)
MX (1) MXPA05000380A (fr)
OA (1) OA12885A (fr)
PA (1) PA8575901A1 (fr)
PE (1) PE20040666A1 (fr)
TN (1) TNSN05014A1 (fr)
TW (1) TW200402416A (fr)
UY (1) UY27897A1 (fr)
WO (1) WO2004009550A1 (fr)
ZA (1) ZA200500067B (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7399790B2 (en) 2001-02-28 2008-07-15 Konowalchuk Thomas W Virucidal compositions

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7493363B2 (en) 2001-09-19 2009-02-17 Microsoft Corporation Peer-to-peer group management and method for maintaining peer-to-peer graphs
US7842693B2 (en) 2002-06-12 2010-11-30 Chemocentryx, Inc. Substituted piperazines
US7589199B2 (en) 2002-06-12 2009-09-15 Chemocentryx, Inc. Substituted piperazines
EP1531822B1 (fr) 2002-06-12 2009-08-05 ChemoCentryx Inc Derives de piperazine 1-aryl-4-substitues utilises en tant qu'antagonistes du ccr1 dans le traitement de l'inflammation et des troubles immunitaires
CA2492110A1 (fr) * 2002-07-18 2004-01-29 Pfizer Products Inc. Derives de piperidine bicycliques utilises comme antagonistes du recepteur de chimiokine ccr1
US8261062B2 (en) 2003-03-27 2012-09-04 Microsoft Corporation Non-cryptographic addressing
US7479496B2 (en) 2004-02-19 2009-01-20 Bristol-Myers Squibb Company Substituted spiro azabicyclics as modulators of chemokine receptor activity
US7230022B2 (en) 2004-02-19 2007-06-12 Bristol-Myers Squibb Company Substituted fused bicyclic amines as modulators of chemokine receptor activity
US7381738B2 (en) 2004-02-19 2008-06-03 Bristol-Myers Squibb Company Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity
US7288563B2 (en) 2004-02-19 2007-10-30 Bristol-Myers Squibb Company Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity
US7435830B2 (en) 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
US7435831B2 (en) 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
US7929689B2 (en) 2004-06-30 2011-04-19 Microsoft Corporation Call signs
GT200500375A (es) * 2004-12-20 2006-11-28 Derivados de piperidina y su uso como agentes antiinflamatorios
US7620902B2 (en) 2005-04-20 2009-11-17 Microsoft Corporation Collaboration spaces
US7617281B2 (en) 2005-04-25 2009-11-10 Microsoft Corporation System and method for collaboration with serverless presence
US7660851B2 (en) 2005-07-06 2010-02-09 Microsoft Corporation Meetings near me
SI1907374T1 (sl) 2005-07-26 2012-11-30 Glaxo Group Ltd Derivati benzilpiperazina uporabni za zdravljenje gastrointestinalnih motenj
WO2007073432A2 (fr) 2005-10-11 2007-06-28 Chemocentryx, Inc. Derives de la piperidine et procedes d’utilisation
US8086842B2 (en) 2006-04-21 2011-12-27 Microsoft Corporation Peer-to-peer contact exchange
US8069208B2 (en) 2006-04-21 2011-11-29 Microsoft Corporation Peer-to-peer buddy request and response
WO2009051244A1 (fr) * 2007-10-18 2009-04-23 Takeda Pharmaceutical Company Limited Composé hétérocyclique
WO2010077915A1 (fr) * 2008-12-17 2010-07-08 Forest Laboratories Holdings Limited Nouveaux composés utiles comme ligands de récepteur de chémokine cc
WO2015091645A1 (fr) 2013-12-18 2015-06-25 Basf Se Composés d'azole transportant un substituant dérivé d'imine

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE640616A (fr) * 1962-12-19
US3492397A (en) * 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
US4060598A (en) * 1967-06-28 1977-11-29 Boehringer Mannheim G.M.B.H. Tablets coated with aqueous resin dispersions
US3538214A (en) * 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
US4173626A (en) * 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
WO1997024325A1 (fr) * 1995-12-28 1997-07-10 Takeda Chemical Industries, Ltd. DERIVES DE DIPHENYLMETHANE UTILISES COMME ANTAGONISTES DU RECEPTEUR MIP-1α/RANTES
CA2373942A1 (fr) * 1999-05-18 2000-11-23 Teijin Limited Remedes ou prophylactase contre les maladies associees a des chimiokines
AR028947A1 (es) * 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
CA2453383C (fr) * 2001-07-24 2010-04-06 Richter Gedeon Vegyeszeti Gyar Rt Derives de piperidine utilises en tant qu'antagonistes du recepteur n-methyl-d-aspartate (nmda)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7399790B2 (en) 2001-02-28 2008-07-15 Konowalchuk Thomas W Virucidal compositions

Also Published As

Publication number Publication date
CA2492651A1 (fr) 2004-01-29
PA8575901A1 (es) 2004-07-20
KR20050021497A (ko) 2005-03-07
US20040063759A1 (en) 2004-04-01
MXPA05000380A (es) 2005-03-31
HN2003000222A (es) 2004-11-23
OA12885A (en) 2006-09-15
JP2005537279A (ja) 2005-12-08
AP2005003200A0 (en) 2005-03-31
ZA200500067B (en) 2005-11-02
TNSN05014A1 (fr) 2007-05-14
ECSP055547A (es) 2005-03-10
EP1534677A1 (fr) 2005-06-01
IS7614A (is) 2004-12-23
IL166010A0 (en) 2006-01-15
AU2003242941A1 (en) 2004-02-09
UY27897A1 (es) 2004-02-27
TW200402416A (en) 2004-02-16
PE20040666A1 (es) 2004-09-25
CN1668592A (zh) 2005-09-14
WO2004009550A1 (fr) 2004-01-29
BR0312946A (pt) 2005-07-12
AR040583A1 (es) 2005-04-13

Similar Documents

Publication Publication Date Title
MA27326A1 (fr) Derives de piperidine et leur utilisation comme inhibiteurs selectifs de la liaison de mip-1 alpha a son recepteur ccr1
HUP0402376A2 (hu) Imidazol-4-karboxamid-származékok, előállításuk és az ezeket tartalmazó, elhízás kezelésére alkalmas gyógyszerkészítmények
MA28432B1 (fr) Antagonistes du recepteur de la chimiokine
ATE269312T1 (de) N-(amidinophenyl)-n'-(subst.)-3h-2,4- benzodiazepin-3-on derivative als faktor xa inhibitoren
DE602004012403D1 (de) Zusammensetzungen zur beeinflussung des gewichtsverlusts
NO20044731L (no) Kinolin- og isokinolinderivater fremgangsmate for fremstilling derav og anvendelse derav som betennelseshemmere
AU2003301020A8 (en) Isoquinolinone derivatives and their use as therapeutic agents
HUP0301573A2 (hu) Szubsztituált arilpirazinok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
ES2124167A1 (es) Nuevos derivados del bencimidazol con actividad antihistaminica.
MA27190A1 (fr) Derives de tropane servant de modulateurs de ccr5
NO20061978L (no) Imidazopyridinsubstituerte tropanderivater med CCR5-reseptorantagonist aktivitet for behandling av HIV og inflammasjon
DE602004023207D1 (de) Benzimidazol-derivate als mek-hemmer
MXPA05007115A (es) Nuevos agonistas inversos del receptor cb 1.
DE60112306D1 (de) Kondensierte pyrazindionderivate als pde5 inhibitore
MA27327A1 (fr) Derives de piperidine bicycliques servant d'antagonistes du recepteur de chimiokine ccr1
NO20012194D0 (no) CRF-reseptorantagonister og tilhörende fremgangsmåter
DE60139382D1 (de) 2-hydroxy-mutilin-carbamat derivate und ihre anwendung als antibakterielle mittel
ATE257834T1 (de) Heterocyclische aminopyrrolidon-derivate als melatonergene wirkstoffe
RU2008127257A (ru) Тризамещенные производные хиназолинона в качестве ваниллоидных антагонистов
MXPA02012470A (es) Inhibidores de fosfodiesterasa especificos para gmp ciclico.
MEP19008A (en) Imidazoquinoline derivatives as adenosine a3 receptor ligands
WO2003066621A8 (fr) Derives de piperidine et leur utilisation en tant qu'antagonistes des tachykinines
DE69817810D1 (de) Cyanoguanidine als zellproliferation inhibitoren
DE60110124D1 (de) Kondensierte pyrazindionderivate als pde inhibitoren
CO5210926A1 (es) Mezclas fungicidas